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In Ayurveda, there is no disease, which can directly 
co-related with Hypertension. As per Ayurveda 
principle, in case of unknown disease, physician 
should try to understand the nature of disease 
through Dosha, Dushya and Samprapti; then should 
initiate the treatment.[1] Rakta Dhatu explained in 
Ayurveda (inclusive of Rasa Dhatu) can be compared 
to the blood tissue. Vyana Vayu is responsible for the 
heart function including the output (Systole) and input 
(Diastole)  of  the  blood  and  the  circulation.  As  per  
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Ayurveda, hypertension can be correlate with Vataj 
Hrudroga.[2] Hypertension is often called the silent 
killer because it shows no early symptoms and, 
simultaneously, is the single most significant risk 
factor for atherosclerosis and all clinical manifestation 
of atherosclerosis. Currently available anti-
hypertensive drugs are either too expensive for long 
term use or often related with side effect like renal 
impairment, headache, oedema etc. hence there has 
been pursuit for new safe and effective drug for 
hypertension. Hence it is necessary to find out some 
human health friendly and cost wise cheap 
formulation to control and eradicate this disease. The 
entire above scenario encouraged to invent a new and 
safe Polyherbal drug Karsha Vati as mentioned in 
Bhavaprakasha Madhyam Khanda for eradication of 
Hrudaygat Vata.[3] According to ancient Ayurvedic text 
and Nighantus all the contains of Karsha Vati [i.e. 
Ashwagandha (W. somnifera),[4] Bibhitaki (Embilica 
officinalis)[5] and Gud (jaggery)],[6] these drugs are 
Hrudya means good for heart and purifies blood and 
enhances blood circulation thus Rasayana and 
increase life expectancy, hence thought to be useful in 
hypertension. 
A B S T R A C T  
Hypertension appears to be the important risk factor of the modern society; the cause behind this is 
busy and stressful life, absence or less physical activities. A clinical study was conducted on patients, 
to evaluate the efficacy of Karsha Vati and Telmisartan in the management of essential Hypertension. 
The present study was designed on newly diagnosed cases of Hypertension. The Aim and Objective of 
this study was to evaluate the efficacy of Karsha Vati and Telmisartan in the management of 
Hypertension. This study was planned on 60 diagnosed cases of Hypertension in each Trial and 
Controlled group who were orally administered with Karsha Vati and Telmisartan respectively. Result 
obtained from study revealed that Karsha Vati (Trial group) shows good effect in relieving the 
subjective criteria’s viz, Shiroruka, Bhrama, Klama, Nidra-vikruti, Hrud-dravata than controlled group. 
There was no significant difference seen between the two groups. 
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AIM AND OBJECTIVE 
To study the clinical efficacy of Karsha Vati in the 
management of Essential Hypertension. 
MATERIALS AND METHODS 
During this study of “Karsha Vati” in essential 
hypertension, pre-decided methodology was adopted. 
60 patients were selected (By Simple Random 
method) for the study and divided into 2 groups. 
Ingroup (I), called as ‘Trial Group’, 30 patients were 
included to whom ‘Karsha Vati’ (2 gm) given twice a 
day before meals for 6 weeks. Another group, called 
as ‘Control Group’, 30 patients were included who 
were given a tablet of ‘Telmisartan’ (20 mg) once daily 
after breakfast for 6 weeks. 
Type of Study - Open Randomized Controlled Study.[7] 
Method of Preparation 
Karsha Vati was prepared under the guidance of 
Bhaishajya Kalpana Department of Smt. K. G. Mittal P. 
Ayurveda College, Mumbai, India as per classical text 
reference. 
Fine powders (Churna) of Ashwagandha, Bibhitaki and 
(Purana & Shuddha) Gud were taken in 1:1:2 
proportion (According to Sharangadhara Samhita).[8] 
Sufficient water was added in above mentioned 
ingredients in a big pan over low fire, which make a 
semisolid matter (i.e. suitable form for preparation of 
tablets) after some time. 
▪ Matter was stirred till end of the recipe; and Then, 
it was dried in a shadow to make the tablets each 
of 500 mg weight; with the help of Tablet-
Preparing-Machine and kept in small plastic 
bottles. 
▪ The drug is given in Vati form for the following 
purposes. 
1. To administer the correct dose. 
2. To palatability of patient. 
Standardization of drugs 
Tablet analysis of Karsha Vati was done at Alarsin 
pharmaceutical Lab. Andheri, Mumbai. 
Dose 
▪ Karsha Vati 2 gm. twice a day before food 
[Aushadha Sevana Kala ‘Pragbhakta’] given 
according to Ayurvedic principles for more 
accurate results to Trial Group. 
▪ Telmisartan had been given in dose of 20 mg after 
breakfast once a day to Control Group. 
Anupana 
Ushnodaka (warm water) to increase the efficacy of 
the drug.[9] 
Duration - 6 weeks. 
Diet and Exercises (Aahara and Vihara) 
They were as per patient’s previous schedule; but not 
with too much oily, fried, non-veg food. Also, too 
much exercises (like Yoga) not permitted during trial 
for 6 weeks. 
Follow-up 
Clinically patients were screened every day for first 
week thenafter weekly screening is done. 
Study Centre - OPD and IPD; Dept. of Kayachikitsa of 
our Institution. 
Criteria of Diagnosis 
Patient with pre-hypertension stage i.e. SBP (120-
139mmHg) and DBP (80-89 mmHg) also Stage 1 
hypertension i.e. SBP (140-180 mmHg) and DBP (90-
99 mmHg) was diagnosed. 
Inclusion criteria 
▪ Both sexes are equally involved in study. 
▪ Age group 30 to 70 years age. 
▪ Newly diagnosed patient of hypertension OR 
patient Known to be Hypertensive but yet not 
approached any system of medication. 
▪ Blood pressure >/= 130 (systolic) & >/= 85 
(diastolic) or specific medication. (130-180 systolic 
& 85-100 diastolic pre hypertension & Stage I (7th 
JNC Criteria & WHO criteria for diagnosis of HTN) 
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Exclusion criteria 
▪ Severe essential hypertension (SBP/DBP is >/= 
180/100 mmHg). Significant Renal insufficiency. 
▪ H/O cerebral Vascular Disease, HIV, AIDS, Hep-B, 
Hep-C, or any other Immunosuppressive disorder. 
▪ Current Diagnosis or H/O of malignancy and any 
Mental Disorder. 
▪ Pregnant or breastfeeding women. 
Withdrawal criteria 
1. Left Against Medical Advice (LAMA) 
2. Aggravation of Symptoms 
3. Development of complications due to presenting 
illness or otherwise 
4. Any adverse drug effects 
Investigations 
1) Blood - CBC, ESR, Liver Function and Renal 
Function Tests, Lipid Profile before treatment as 
routine and to exclude complications said in 
Exclusion Criteria as per requirement. 
2) Blood Sugar (Fasting and Post-Prandial) before 
treatment as routine and to avoid Diabetes 
Mellitus as per requirement. 
3) X – Ray (Chest) PA view before treatment as 
routine to avoid Respiratory Diseases as per 
requirement. 
4) ECG before treatment as routine to avoid Cardiac 
Diseases Complications as per requirement. 
Criteria of assessment 
Assessment was done subjectively as well as 
objectively. 
Subjective criteria 
Symptoms of Hypertension mentioned in the text or 
practically observed was assessed at each follow- up 
and presence or absence of them was registered. All 
symptoms were graded into five grade scales (0-4) on 
the basis of severity to assess the changes and this 
study in gradation was done at each follow up. 
Gradation of symptoms[10] 
These gradations are given by CCRAS and also 
practically observed in essential hypertension.  
Table 1: Gradation of symptoms 




Headache relieves without 
medication. 
1 
Frequent headache relieves with 
rest doesn’t disturb daily routine. 
2 




Continuous or severe headache 
disturbs sleep and daily activities 







Rarely for some movement during 
change of posture. 
1 
Often for some movement during 
change of posture. 
2 
Often for each movement even in 
lying down position. 
3 
Patient unable to hold himself 





Rarely feeling of tiredness without 
any exertion. 
1 
Rarely feeling of tiredness without 
any exertion with inability in 
concentration. 
2 
Frequently feeling of tiredness 
without any exertion with inability 
in Concentration. 
3 
Continuous feeling of tiredness 
without any exertion with inability 
4 
Vd. Sunil B. Patil et al. Efficacy of Karsha Vati and Telmisartan in the management of Essential Hypertension 
ISSN: 2456-3110                                                            CASE REPORT Sept-Oct 2020 
 









Disturbed sleep wakes up1-2 times. 1 
Difficult to onset of sleep remains 
disturbed all night. 
3 
Very less sleeping small intervals 
makes patient irritable. 
4 







Palpitation rarely 1 
Palpitation sometimes. 2 
Palpitation on exertion 3 
Palpitation at rest 4 
Table 2: Effect on symptoms of 30 patients of Trial 
group - Subjective Parameters (Intra-Group 
Comparison) by Wilcoxon-Matched-Pairs Signed-
Ranks Test. 













1. Shiroruk  BT 1.87 
± 
0.63 










2. Bhrama BT 1.47 
± 
0.73 


















































Table 3: Effect on symptoms of 30 patients Of 
Control group by Wilcoxon-Matched-Pairs Signed-
Ranks Test. 













1. Shiroruk BT 1.77 
± 
0.68 










2. Bhrama BT 1.83 
± 
0.70 
0.13 300.00 24 < 
0.0001 
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3. Klama BT 1.87 
± 
0.86 








































Table 4: Showing comparison between two groups 
















1. Shiroruk Trial 1.87 
± 
0.63 








1.51 2.02 nt 
2. Bhrama Trial 1.47 
± 
0.73 











3. Klama Trial 1.30 
± 
0.65 





































This test was performed to show homogeneity of the 
data between two groups. The test was applied to 
symptom score. The value of P>0.05 (except Klama) 
which was statistically insignificant. Hence, gradations 
of symptoms in both groups were at same level which 
means that data was homogenous in nature.  
Table 5: Showing comparison between two groups 














1. Shiroruk Trial 0.80 
± 
0.61 
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0.61 
2. Bhrama Trial 0.50 
± 
0.57 











3. Klama Trial 0.23 
± 
0.50  










































There was no significant difference found between 
Trial and Control group in all symptoms. The P value is 
>0.05 (except Klama and Nidra Vikruti), which means 
the drug in Trial group was equally effective as in 
control group with respect to above symptoms. In 
case of ‘Klama and Nidra Vikruti’, the trial drug 
showed more improvement as compared to 
controlled drug with P value less than 0.05.  
Table 6: Showing effect on objective Parameters of 
60 patients of Essential hypertension by paired ‘t’ 
test. 
Trial Group – Objective Parameters (Intra – Group 
Comparison): (Paired t test) 
SN Symptom  Mean ± SD SEd t value P 
value 
1. SBP BT 149.33 ± 
8.14 
1.49 9.997 < 
0.0001 
AT 143.2 ± 
7.89 
1.44 
Diff. 6.13 ± 3.30 0.61 
2. DBP BT 89.73 ± 
3.14 
0.57 11.164 < 
0.0001 
AT 85.20 ± 
3.04 
0.56 
Diff. 4.53 ± 2.22 0.41 
Control Group – Objective Parameters (Intra – Group 
Comparison): (Paired t test) 




1. SBP BT 152.27 ± 
10.75 
1.96 15.168 < 
0.0001 
AT 140.07 ± 
10.11 
1.84 
Diff. 12.20 ± 4.41 0.80 
2. DBP BT 89.20 ± 3.35 0.61 19.568 < 
0.0001 
AT 80.53 ± 3.52 0.64 
Diff. 8.67 ± 2.43 0.44 
Showing effect on Objective Parameters of 60 
patients of Essential hypertension by paired ‘t’ test. 
▪ Systolic blood pressure values were decreased in 
Trial group by 6.13 ± 3.30. Paired t was 15.168. P < 
0.0001, which was statistically extremely 
significant.  
▪ In case of Control group, systolic blood pressure 
was decreased by 12.20 ± 4.41. Paired t was 
15.168.  P< 0.0001, which was statistically 
extremely significant.  
▪ Diastolic blood pressure values were decreased in 
Trial group by 4.53 ± 2.22. Paired t was 11.164. P < 
0.0001, which was statistically extremely 
significant.  
▪ In case of Control group, diastolic blood pressure 
was decreased by 8.67 ± 2.43. Paired t was 
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19.568.  P< 0.0001, which was statistically 
extremely significant.  
Table 7: Showing comparison between two groups 
by Unpaired ‘t’ Test on objective parameters. 
Inter – Group Comparison – Objective Parameters – 


































































Inter – Group Comparison – Objective Parameters – 































































Statistical Analysis of the effect of therapy on 
Objective parameters of 60 patients of Essential 
hypertension by Unpaired ‘t’ test:  
Before treatment 
▪ Systolic blood pressure Mean of difference in Trial 
group was 149.33 ± 8.14, which was compared 
with that of mean of difference in Control group. 
It was 152.27 ± 10.75. Unpaired t was 1.192; P > 
0.05 not significant, which suggests that 
difference of mean exhibited by Control group 
was insignificant.  
▪ Diastolic blood pressure Mean of difference in 
Trial group was 89.73 ± 3.14, which was compared 
with that of mean of difference in Control group. 
It was 89.20 ± 3.35. Unpaired t was 0.6366; P > 
0.05, which suggests that difference of mean 
exhibited by Control group was insignificant. 
After treatment  
▪ Systolic blood pressure Mean of difference in Trial 
group was 143.20 ± 7.89, which was compared 
with that of mean of difference in Control group. 
It was 140.07 ± 10.11. Unpaired t was1.338; P > 
0.05, which suggests that difference of mean 
exhibited by Control group was insignificant.  
▪ Diastolic blood pressure Mean of difference in 
Trial group 85.20 ± 3.04, which was compared 
with that of mean of difference in Control group. 
It was 80.53 ± 3.52. Unpaired t was 5.492; P <0.05, 
which suggests that difference of mean exhibited 
by Trial group was significant difference. 
Table 8: Showing effect on symptoms score of 60 






































56 24 32 57.1
4% 




44 15 29 65.9
1% 
55 25 30 54.5
5% 
3. Klama 39 07 32 82.0
5% 
56 30 26 46.4
3% 
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56 09 47 83.9
3% 





31 17 14 45.1
6% 



















Effect of therapy on symptom score: It was observed 
that overall percentage of relief was more in Trial 
group (66.84%) than in Control group (51.75%). The 
symptoms such as Shiroruk, Bhrama, Klama, Nidra-
Vikruti, and Hrud-dravatva were studied in this trial as 
described here before in table. Percentage of relief for 
all the symptoms is more in Trial group (except Hrud-
dravatva). 
Effect of therapy on blood pressure: It was observed 
that overall percentage of relief was more in control 
group (8.864%) than in trial group (4.573%). 
Telmisartan is more accurate on management of 
hypertension from initial dose. 
DISCUSSION 
Diet and lifestyle are major factors to influence 
susceptibility to many diseases. Man has adapted 
himself to the fast-paced life by modifying dietary and 
lifestyle preferences to suit this modern era. This has 
resulted in a state of discrepancy between the 
external environment and internal mechanism causing 
many diseases which are popularly referred as 
‘lifestyle-diseases’ and “essential hypertension” is one 
of them. 
There is no precise terminology for Essential 
hypertension mentioned in the Ayurveda Classics. 
Causative factors of Vyana Vayu, Rasa-Rakta Dhatu, 
Hrudaya Roga and Essential hypertension are having 
direct relation with Vata Dosha, hence being close 
resemblance in terms of Nidanas the disease Essential 
hypertension can be correlated with Vataja Hrudroga.  
Essential hypertension requires long term treatment 
and no drug in modern science is able to treat the 
basic pathology of the disease completely and prevent 
progression without complications. Hence, the world 
is looking towards Ayurveda the ray of hope. The 
present scenario regarding essential hypertension has 
encouraged me to work on this disease with the help 
of a Polyherbal Combination Karsha Vati. 
Discussion on mode of action of Karsha Vati 
In the pathogenesis of Essential Hypertension main 
factors are Vata Vrddhi, Rasa - Rakta 
Dhatwagnimandya and vitiated Kapha with Pitta. So 
here ‘Karsha Vati” had been selected to breakdown 
its Samprapti. The ‘Karsha Vati’, due to its Laghu Guna 
and Ushna Virya may conquer the Dhatwagnimandya 
and do strengthening of Hrudaya. 
Discussion on Total Effect of Therapy 
Comparison of Ordinal Data between two groups was 
statistically evaluated by “Mann-Whitney test”. The 
value of Mann Whitney ‘U’ Static is 311.5 and P-value 
is more than 0.05 (except Klama and Nidra Vikruti), 
which was statistically insignificant suggestive of no 
significant difference between two groups with 
respect to effect of therapy on Subjective Criteria. In 
case of ‘Klama and Nidra Vikruti’, the trial drug 
showed more improvement as compared to 
controlled drug with P value less than 0.05.   
Comparison of Numerical Data between two groups 
was statistically evaluated by “Unpaired-t test”. The 
value of  ‘t’ is 1.338 and P-value is more than 0.05, 
which was statistically insignificant suggestive of no 
significant difference between two groups with 
respect to effect of therapy on Objective Criteria.  
CONCLUSION 
In this trial patients had shown better results in both 
the groups i.e. Trial group (Karsha Vati) and Control 
group (Telmisartan). There is a significant reduction in 
diastolic blood pressure in trail group, while not so 
significant difference in systolic blood pressure levels 
in both the groups is noted. It was observed that 
overall percentage of relief in symptoms is more in 
Trial (66.84%) than in Control group (51.75%). It was 
observed that overall percentage of relief in managing 
raised blood pressure was more in control group 
(8.864%) than in trial group (4.573%). Telmisartan is 
more accurate on management of hypertension from 
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initial dose. Hence it can be stated that, Karsha Vati 
has less effect than telmisartan in management of 
essential hypertension. 
REFERENCES 
1. Acharya charaka, charak Samhita of agnivesha with 
charak Chandrika hindi commentary, vol 1, 
sutrasthana, trishothiya adhayaya no. 18, shloka no. 
44-45, edited by Dr.Brahmanand Tripathi, Chaukhamba 
Surbharati prakashan, Varanasi, first edition 2014. 
2. Acharya Vagbhata, Ashtang Hrudaya with Nirmala 
commentary, Nidansthana, Rajyakshama Nidan 
Adhayaya no.5, shloka no. 39-40, page no. 465, edited 
by dr.Brahmanand Tripathi, chaukhamba Sanskrit 
pratisthan, delhi 2011. 
3. Pandit SriBhahma Sankaramisra, Shri BhavMishra, 
Bhavprakash (Vol. II), Vatvyadhiadhikar, Chikitsa 
prakaran 8/252, page no.269, Chaukhambha Sanskrit 
Bhawan, Varanasi-2016. 
4. Shri Bhavmisra, Bhavprakasha with vidyotinihindi 
commentary, Guduchyadivarga, Ashwagandha, Shlok 
no. 190, page no. 393, edited by Shri 
brahmasankarmisra and shri rupalalaji Vaishya, 9th 
edition, chaukhamba Sanskrit sansthan, Varanasi, 1991 
5. Shri Bhavmisra, Bhavprakasha with vidyotinihindi 
commentary, Haritakyadivarga, Bibhitaki, Shlok no. 36-
37, page no. 9, edited by Shri brahmasankarmisra and 
shri rupalalaji Vaishya, 9th edition, chaukhamba 
Sanskrit sansthan, Varanasi, 1991. 
6. Shri Bhavmisra, Bhavprakasha with vidyotinihindi 
commentary, Ikshuvarga, gud, Shlok no. 24-26, page 
no. 795, edited by Shri brahmasankarmisra and shri 
rupalalaji Vaishya, 9th edition, chaukhamba Sanskrit 
sansthan, Varanasi, 1991. 
7. B.K. Mahajan, edited by Arun Bhadra Khannal, Method 
in statistics, Sampling 6, page no- 80, Jaypee Brothers 
Medical Publications, Delhi, 2010  
8. Pandit sarandhara, Sarangdhara Samhita with 
Anjananidana of Mahrshi Agnivesha with Dipika hindi 
commentary, madhyamkhanda, adhyaya no 7, shloka 
no. 2-5, edited by Dr. Brahmanand Tripathi, 
chaukhamba surbharati prakashan, reprint edition 
2011, Varanasi. 
9. D.V. pandit, Vd. Ayodhya Pandey; Ashtanga Sangraha 
of Vagbhata with Indu vyakhya; 1st edition, CCRAS. 
Delhi, 1991. 
10. Clinical research Protocol for Traditional Health 
sciences (Ayurveda, Yoga, Naturopathy, Unani, Siddha, 
and Homeopathy) Randomized double blind controlled 
clinical trial of AYUSH. Hypertension, Delhi 2010. 
11. Acharya Charaka, Charak Samhita with Ayurveda dipika 
Ayusi hindi commentary, vol 1, chikitsasthana, 
raktapitta chikitsa adhayaya no. 4, shloka no. 6, page 
no 140, edited by vd. Harishchandra singh Kushwaha, 
2nd edition, chaukhamba Orientalia, Varanasi, 2017. 
12. Maharshi Sushruta, Sushruta Samhita with 
Ayurvedatatva-sandipika commentary vol 1, 
sutrasthana, Shonitvarniyaadhayaya no. 14, shloka no. 





How to cite this article: Vd. Sunil B. Patil, Vd. Sandeep 
K. Patel. Open randomised controlled study to evaluate 
the efficacy of Karsha Vati and Telmisartan in the 
management of Essential Hypertension: A Pilot Study. J 
Ayurveda Integr Med Sci 2020;5:604-612. 
 
Source of Support: Nil, Conflict of Interest: None 
declared. 
Copyright © 2020 The Author(s); Published by Maharshi Charaka Ayurveda Organization, Vijayapur (Regd). This is an open-access 
article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 
 
